But when it reaches the market, here's what to expect based on the current GLP-1 insurance landscape: If Approved for Type 2 Diabetes Most commercial insurance plans will cover it, especially if it demonstrates A1C reduction comparable to or exceeding tirzepatide Prior authorization will likely be required Step therapy (try metformin first, then other agents) is standard Copays with manufacturer savings: potentially $25$50/month If Approved for Obesity/Weight Management Coverage remains highly variable, and many plans still exclude weight management medications Medicare Part D: Congress has been debating coverage of anti-obesity medications, but it remains excluded as of early 2026 Self-insured employers increasingly adding GLP-1 coverage, but it's employer-specific Expect significant prior authorization requirements (BMI thresholds, failed diet attempts) The practical reality: even when retatrutide is approved, many people will face the same insurance barriers that currently exist for Wegovy and Zepbound
268 In vascular smooth muscle cells, uric acid-induced activation of MAPKs promotes the expression of MCP-1, an important chemokine involved in atherosclerosis progression
Alternating between the abdomen, the front of the thighs, and the back of the upper arms gives each spot time to recover and prevents the small lumps that can form when one area is overused
Orphanet J Rare Dis 13(1):219
Journal of the National Cancer Institute 60, 86169
